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Mutations in the TP53 gene not only inactivate its tumor suppressor function but also confer this transcription
factor with gain-of-function oncogenic properties. A recent paper by Zhu and colleagues reveals a novel mo-
lecular pathway driven by mutant p53 and the COMPASS chromatin-modifying complex that is amenable to
pharmacological inhibition.p53 is the most commonly inactivated tu-
mor suppressor in human cancer. About
half of all tumors carry mutations in the
TP53 gene, leading to the expression of
mutant proteins with an impaired ability
to bind DNA and transactivate genes
involved in cell cycle arrest, apoptosis,
and various signaling pathways mediating
the cellular response to stress. In the other
half of tumors, wild-type p53 is inactivated
by alternativemeans, such as hyperactiva-
tion of its endogenous repressors MDM2
and MDM4. Importantly, mutant p53 often
displays gain-of-function (GOF) oncogenic
properties, promoting cancer cell survival,
proliferation, and invasion (Freed-Pastor
and Prives, 2012). Thus, with a single point
mutation, cancer cells not only evade one
of the most potent tumor suppressive
gene networks but also acquire novel ma-
lignant properties.
In the age of precision cancermedicine,
many efforts are devoted to strategies
aimed at restoring normal p53 function
for selective elimination of cancer cells.
The most promising strategy so far re-
sides on small-molecule inhibitors of the
p53-MDM2 interaction, which are cur-
rently being tested in myriad clinical trials
(Brown et al., 2009). These molecules
could benefit 11 million cancer patients
worldwide whose tumors express wild-
type p53. For the other half of patients
whose tumors express mutant p53, hope
resides in either the development of small
molecules binding to the mutant protein
and restoring its wild-type conformation
or strategies targeting acquired genetic
susceptibilities precipitated by GOF p53.
The latter strategy, termed ‘‘synthetic
lethality with mutant p53,’’ representsthe proverbial Holy Grail of the field, an
elusive entity of untold value pursued by
many and attained by none. In a recent
paper, Zhu et al. (2015) describe a novel
molecular pathway driven by GOF p53
that could pave the road for therapeutic
strategies targeting tumors expressing
mutant p53.
Using genome-wide measurements of
p53 chromatin occupancy in a panel of
breast cancer cell lines, Zhu et al. (2015)
observed that mutant p53 not only failed
to recognize the canonical p53 response
elements (p53REs) but also acquired bind-
ing to many genomic sites devoid of
p53REs. Subsequent analysis of these
genomic regions bound by GOF p53
confirmed previous findings by Do et al.
(2012), demonstrating thatmutant p53 iso-
forms are recruited to chromatin via inter-
action with the transcription factor ETS2.
Although wild-type p53 also binds ETS2,
it does so at a much lower affinity. Thus,
GOF mutations foster allosteric enhance-
ment of an otherwise weak biochemical
interaction between these two transcrip-
tion factors (Do et al., 2012). Because
mutant p53 accumulates at high intracel-
lular levels due to the disruption of a nega-
tive feedback loop involving MDM2 trans-
activation bywild-type p53, the cumulative
effect of a strengthened interaction with
ETS2 and the increased stoichiometry
confers mutant p53 with a novel cellular
function at ETS2 target loci. Importantly,
GOF p53 retains two intact transactivation
domains in its N terminus capable of re-
cruiting many transcriptional coactivators
to ETS2 target genes.
Among the target loci bound by GOF
p53, Zhu et al. (2015) noticed strong bind-Cancer Cell 28ing and induction of several chromatin
regulators, including the MLL1 and MLL2
subunits of the lysine methyltransferase
complex COMPASS and the lysine
acetyl-transferase MOZ. Furthermore,
they demonstrated that expression of
MLL1, MLL2, and MOZ is dependent on
mutant p53 and ETS2 but not wild-type
p53. Could this novel pathway represent
a targetable susceptibility in cancer cells
expressing mutant p53? Indeed, using
knockdowns and small molecule inhibi-
tors of the COMPASS complex, Zhu
et al. (2015) observed selective inhibition
of proliferation for cancer cells expressing
GOF p53 both in vitro and in xenograft-
based tumor models.
These results reveal a potentially unique
therapeutic opportunity in the clinical
setting through selective growth inhibition
of human cancers expressingmutant p53.
However, the road to a clinical application
is likely to be longandwinding. Thepapers
by Do et al. (2012) and Zhu et al. (2015)
agree with respect to the biochemical
interaction of ETS2 with various mutant
p53 isoforms, including those targeting
the amino acid residues at positions 175,
248, 249, and 273. However, and quite
importantly, it remains to be determined
to what degree the GOF p53 > ETS2 >
MLL axis applies to the dozens of p53
mutations commonly observed in the
clinic. Another issue that awaits deeper
examination is the prevalence, or lack
thereof, of the differential effects of
COMPASS inhibition across diverse can-
cer types where p53 mutations are com-
mon. Through analysis of expression
data for hundreds of tumors across
different cancer types, Zhu et al. (2015), October 12, 2015 ª2015 Elsevier Inc. 407
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Figure 1. Alternative Modes of Deregulation of the COMPASS Complex in Human Cancer
In leukemias, MLL translocations with >50 possible partners lead to deregulation of COMPASS activity. In
many cases, the chimera involves subunits of the super elongation complex (SEC), such as various AFF
subunits, ELL, and ENL. Mistargeting of the SEC to MLL target loci, such as the HOXA gene cluster, leads
to changes in gene expression that promote proliferation and block differentiation. In solid tumors, gain-of-
function (GOF) p53 mutations lead to abnormal recruitment of mutant p53 containing active trans-
activation domains to ETS2 target genes, such as those encoding the COMPASS subunits MLL1-2. In
turn, overexpression of MLLs leads to increased expression of HOXA genes. Thus, deregulation of
COMPASS activity may underlie alternative paths to malignancy through MLL translocation and p53
mutations in leukemia and solid tumors, respectively.
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diverse tumors expressing mutant p53,
suggesting a conserved pathway beyond
breast cancer cell lines. From a clinical
perspective, the model put forth by Zhu
et al. (2015) would be most valuable for
aggressive cancer types with high rates
of p53 mutations and a dearth of thera-
peutic strategies, such as ovarian and
pancreatic cancers. Another consider-
ation is the issue of toxicity, because
COMPASS inhibitors may have side ef-
fects that prevent their clinical application.
Perhaps the most provocative aspect of
the work by Zhu et al. (2015) is that it
reveals a molecular cascade, potentially
linking a number of previous observations
about the roles of p53 mutations,
COMPASS deregulation, and ETS2 in ma-
lignant transformation. Members of the
MLL family, includingMLL1andMLL2acti-
vated by GOF p53, are common targets
of chromosomal translocations in acute
myeloid and lymphocytic leukemias (AML
andALL) (Smithetal., 2011).These translo-
cations lead to MLL chimeras with >50408 Cancer Cell 28, October 12, 2015 ª2015partner genes, resulting in deregulated
gene expression. The most prominent
among the genes commonly upregulated
in leukemias carrying MLL-fusions are
those in the HOXA cluster of homeotic
genes,which, in turn, promote proliferation
andblockdifferentiation, effectively driving
leukemogenesis. Interestingly, Zhu et al.
(2015) found that GOF p53 also leads to
increased expression of HOXA cluster
genes in breast cancer cells in the absence
of MLL chimeras. Of note, GOF p53 muta-
tions are relatively rare in AML and ALL.
Thus, it is tempting to speculate that the
MLL > HOXA pathway may be activated
by alternative mechanisms in leukemias
and solid tumors via chromosomal MLL
translocations and p53mutations, respec-
tively (Figure 1).
Although ETS2 has been characterized
as an oncogene in specific leukemias and
solid tumors (Li et al., 2014; Sementch-
enko et al., 1998; Simpson et al., 1997),
it has also been defined as a tumor sup-
pressor in lung cancer (Kabbout et al.,
2013). Interestingly, ETS2 is encoded onElsevier Inc.chromosome 21, and increased ETS2
gene dosage in individuals with trisomy
21 has been postulated to explain both
the increased risk of pediatric leukemias
and decreased rate of solid tumors
observed in the population with Down
syndrome (Wolvetang et al., 2003).
Notably, mild overexpression of ETS2 in
mouse models and cell cultures leads to
upregulation of wild-type p53 and p53-
dependent apoptosis for specific cell
types (Wolvetang et al., 2003). Similar to
most ETS family members, ETS2 activity
is stimulated by growth factor signaling.
Thus, ETS2 hyperactivation via oncogenic
signaling may trigger a failsafe mecha-
nism by activating p53 and slowing
down cell proliferation, potentially driving
selection of p53 mutant cells during can-
cer evolution. In turn, these mutations
would enable the GOF p53 pathway
involving MLL transactivation by mutant
p53-ETS2 complexes as described by
Zhu et al. (2015) (Figure 1).
In sum, although much work remains to
be done before these observations could
be applied in the clinic, the Holy Grail
may exist after all, and the COMPASS
may be pointing to it.
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